A treatment that AstraZeneca acquired for up to $6 billion in 2020 is showing early promise as a combination agent in lung cancer, where it’s being tested alongside Merck & Co.’s Keytruda.

The CEO recently led Upstream through a $200 million financing that will support development of an inflammatory disease drug. “We have what investors probably want at this time,” she told BioPharma Dive.

After Indiana’s governor signed a near-total abortion ban into law, the drugmaker said it will rethink future hiring in the state.

The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.

Highly anticipated trial results for Lumakras combinations with immunotherapy fell short of expectations, showing significant liver toxicity that limited dosing.

The company plans to ask regulators to approve its KarXT therapy based on the results, which one analyst called “as good as one could hope for.”

The acquisition gives Pfizer access to Oxbryta, an approved drug for the blood condition, as well as two experimental medicines.

MiroBio, which was spun out of the University of Oxford three years ago, drew Gilead’s interest with its autoimmune disease research.

Enhertu is the first targeted treatment cleared for breast cancers that are ‘HER2 low,’ a new classification that could change how doctors treat the disease.

The agency issued Acadia a complete response letter for pimavanserin, for which the company had sought to win an expanded clearance in Alzheimer’s disease psychosis.

The pharma said Thursday the FDA had accepted its application for donanemab, starting a six month evaluation for potential accelerated approval.

“We're prepared to take our response to the next level in addressing this virus, and we urge every American to take monkeypox seriously,” HHS Secretary Xavier Becerra said Thursday.